-transparent.png){kind=logo}
Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0%-10%). Toxicities of grade > or = 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.
Related Publications
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
January 1994,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
January 1994,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
July 1996,
Anti-cancer drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
January 1995,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
February 1991,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
July 1992,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
November 1993,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
April 1992,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
January 1993,
Investigational new drugs,
T R Jenkins, and
C Tangen, and
J S Macdonald, and
G Weiss, and
R Chapman, and
A Hantel
October 1991,
Journal of immunotherapy : official journal of the Society for Biological Therapy,
